Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25607591 | 0.93 | LMNA (0.63) | DRD2LMNAHTR1AGAAADRA1D | |
| SCHEMBL12040648 | 0.87 | ALDH1A1 (0.57) | DRD2LMNAHTR1AGAAADRA1D | |
| SCHEMBL1725518 | 0.84 | LMNA (0.54) | DRD2LMNAHTR1AGAAADRA1D | |
| SCHEMBL1725203 | 0.84 | LMNA (0.56) | DRD2LMNAHTR1AGAAADRA1D | |
| SCHEMBL4865184 | 0.83 | HTR6 (0.62) | DRD2DRD3LMNAHTR1AGAA | |
| SCHEMBL4250844 | 0.83 | GAA (0.57) | DRD2DRD3LMNAHTR1AGAA | |
| SCHEMBL4252010 | 0.83 | LMNA (0.47) | DRD2DRD3LMNAHTR1AGAA | |
| SCHEMBL9332781 | 0.80 | ALDH1A1 (0.48) | LMNAHTR1AGAAALDH1A1MAPT | |
| SCHEMBL1383370 | 0.79 | HTR1A (0.72) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL9055949 | 0.78 | HTR1A (0.65) | DRD2DRD3LMNAHTR1AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1892238-A1 | 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1892238-A1 | 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | CCR10, H1-10, VCAM1 | DRD2 746/4885DRD3 638/4885LMNA 3467/4885 |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | CCR10, H1-10, CXCL10 | DRD2 768/4885DRD3 610/4885LMNA 3212/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | DRD2 563/4885DRD3 224/4885LMNA 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.